Major Pharmaceutical Firm Horizon Therapeutics Plans 22 Layoffs at Rockville Centre

Horizon Therapeutics, in a WARN filing, stated that layoffs at its Rockville location will be effective from May 8.

Written By Deepali Singla
Amgen acquired Horizon Therapeutics to expand its treatment portfolio for rare diseases (Image credit: Towfiqu Barbhuiya | Pexels | Created on Canva)

Horizon Therapeutics, a subsidiary of a biotech company, will lay off employees from a center in Rockville, Maryland. Affected employees are given a notice period of 60 days under the WARN Act.

Horizon Therapeutics Under Amgen to Layoff Employees

Horizon Therapeutics USA, Inc. has filed a WARN notice on March 9, 2026. Located at 9605 Medical Center Drive, Suite 325, Rockville, Maryland, the facility has announced a mass layoff, no recall. This means laid-off workers are not supposed to be recalled after the layoffs become effective.

The separation will commence on May 8, 2026. 22 employees will be laid off as indicated in the filing.

Such notices are filed under the Worker Adjustment and Retraining Notification (WARN) Act. It requires employers to give advance notice of large-scale layoffs or the closure of facilities. This allows workers and local governments to make preparations in case of employment transitions.

Horizon Therapeutics specializes in medicines for rare and rheumatic diseases. Amgen acquired Horizon Therapeutics in October 2023 with an investment of $27.8 billion. The programs and therapies of Horizon became a part of the overall research and commercial business of Amgen.

Amgen is a multinational biotechnology firm involved in the discovery, development, production, and delivery of novel human therapeutics. The company works on medicines that treat serious illnesses like oncology, cardiovascular disease, inflammation, and rare diseases.

Amgen has research and manufacturing plants in a number of countries and has multiple employees around the world as a part of its international network of biopharmaceutical companies.

The WARN filing reflects the uncertainty of jobs within the biopharmaceutical sector. It is a constantly evolving industry in terms of skills and product demand, hence affecting job roles every now and then.

Love our content?
Add WhatNow as a preferred source on Google to see more of our trusted coverage when you search.

Be the First to Know

From new restaurant openings to exciting retail launches and real estate insights, be the first to know what’s happening in Washington D.C.

Share This Article
Follow:
Deepali Singla is a food technologist by discipline and a seasoned, versatile writer by profession. Her passion for writing emerged during her academic journey. With a strong foundation in research, she excels at crafting well-researched content. Combining technical knowledge with a flair for storytelling, Deepali brings depth and clarity to her work.
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *